Previous close | 12,871.00 |
Open | 12,734.00 |
Bid | 12,477.01 x 100 |
Ask | 14,699.97 x 10000 |
Day's range | 12,477.00 - 12,734.79 |
52-week range | 7,452.75 - 13,844.99 |
Volume | |
Avg. volume | 292 |
Market cap | 12.183T |
Beta (5Y monthly) | 0.37 |
PE ratio (TTM) | 108.69 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 87.85 (0.70%) |
Ex-dividend date | 14 Feb 2024 |
1y target est | N/A |
Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first quarter of 2024.
Eli Lilly and Company (NYSE: LLY) today announced positive topline results of the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints. Percentage change in AHI was a key secondary endpoint in both studies. AHI records the number of times a person's breathing shows a restricted or complete block of airflow per hour of sleep and is used to evaluate the sever
Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2024 financial results on April 30, 2024. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.